November 3, 2021
WA DOH Updates Guidance on Use of Monoclonal Anti-SARS-CoV-2 Antibodies
Note: This advisory modifies and supersedes previous guidance issued on this topic September 17, 2021.
Reason for Update
The shortage of anti-SARS-CoV-2 monoclonal antibodies (mAbs) in Snohomish County and statewide that occurred during September 2021 has improved. WA DOH has now issued updated statewide interim guidance on prioritization of access to mAbs, rendering the former local guidelines defunct and rescinded. The Health District does not have an ongoing role in the financing, distribution, or clinical guidance for mAbs. Please direct any enquiries to email@example.com. Thank you for your patience with this and other frequent and short-term changes in COVID-19 guidance.
- Consideration for use as post-exposure prophylaxis in certain limited high-risk settings or groups (e.g., long-term care, other congregate settings, moderate-to-severe immunosuppression)
- Reduction in age threshold for use among fully vaccinated patients to ≥65 years and among not fully vaccinated patients down to ≥50 years of age
- Inclusion of pregnancy as an indication among both fully vaccinated and not-fully vaccinated patients
- Reduction in BMI threshold for use among not-fully vaccinated patients to ≥25 kg/m2 (or ≥85th percentile for children12-17 years of age based on CDC growth charts)
- Inclusion of groups with limited access to care or that have been disproportionately impacted by COVID-19
Prior to implementing these updates, please read the entire 3-page document to appreciate the full perspective, details, and nuances of WA DOH’s newly issued guidance.